Current
Neuro-Oncology


Volume 22 Number 10
October 2020


Home > Publications > Current Neuro-Oncology > Volume 22, Year 2020 > Number 10, October



Contents


Central nervous system tumors


Gliomas


High-grade gliomas


Low-grade gliomas


Diffuse astrocytic and oligodendroglial tumors


Glioblastoma


Diffuse Midline Glioma


Anaplastic Oligodendroglioma


Other gliomas


Chordoid glioma of the third ventricle


Embryonal tumors


Medulloblastoma


Tumors of the sellar region


Craniopharingioma



Central nervous system tumors


Dudley HJ, Ren ZJ, Bortz DM.
Brain tumor classification in MRI image using convolutional neural network.
Math Biosci Eng. 2020 Sep 15. 2020;17(5):6217-6239. doi: 10.3934/mbe.2020329. Artificial intelligence analysis. _




Fangusaro J, Mitchell DA, Kocak M, Robinson GW, Baxter PA, Hwang EI, Huang J, Onar-Thomas A, Dunkel IJ, Fouladi M, Warren KE.
Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
Pediatr Blood Cancer. 2020 Oct 7. 2020;e28756. doi: 10.1002/pbc.28756. Phase 1 trial. _




Ginalis EE, Danish SF.
Magnetic resonance-guided laser interstitial thermal therapy for brain tumors in geriatric patients.
Neurosurg Focus. 2020 Oct;49(4):E12. doi: 10.3171/2020.7.FOCUS20462. Retrospective analysis. _




Journy NMY, Zrafi WS, Bolle S, Fresneau B, Alapetite C, Allodji RS, Berchery D, Haddy N, Kobayashi I, Labbé M, Pacquement H, Pluchart C, Schwartz B, Souchard V, Thomas-Teinturier C, Veres C, Vu-Bezin G, Diallo I, de Vathaire F.
Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study.
Cancer Epidemiol Biomarkers Prev. 2020 Oct 8. doi: 10.1158/1055-9965.EPI-20-0735. Epidemiology analysis. _




Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS.
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
Neuro Oncol. 2020 Oct 30. 2020;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200. Epidemiology analysis. _




Stauffer PR, Rodrigues DB, Goldstein R, Nguyen T, Yu Y, Wan S, Woodward R, Gibbs M, Vasilchenko IL, Osintsev AM, Bar-Ad V, Leeper DB, Shi W, Judy KD, Hurwitz MD.
Feasibility of removable balloon implant for simultaneous magnetic nanoparticle heating and HDR brachytherapy of brain tumor resection cavities.
Int J Hyperthermia. 2020 Oct 13. 2020;37(1):1189-1201. doi: 10.1080/02656736.2020.1829103. Preclinical study. _



Gliomas


Forster MT, Behrens M, Lortz I, Conradi N, Senft C, Voss M, Rauch M, Seifert V.
Benefits of glioma resection in the corpus callosum.
Sci Rep. 2020 Oct 6. 2020;10(1):16630. doi: 10.1038/s41598-020-73928-x. Prospective study. _




Gao M, Huang S, Pan X, Liao X, Yang R, Liu J.
Machine Learning-Based Radiomics Predicting Tumor Grades and Expression of Multiple Pathologic Biomarkers in Gliomas.
Front Oncol. 2020 Sep 11. 2020;10:1676. doi: 10.3389/fonc.2020.01676. Radiomics analysis. _




Kondo N, Hikida M, Nakada M, Sakurai Y, Hirata E, Takeno S, Suzuki M.
Glioma Stem-Like Cells Can Be Targeted in Boron Neutron Capture Therapy with Boronophenylalanine.
Cancers (Basel). 2020 Oct 19. 2020;12(10):3040. doi: 10.3390/cancers12103040. Laboratory investigation. _




Ma L, Li G, Wei M.
Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II-IV Glioma Recurrence.
Cancer Manag Res. 2020 Sep 30. 2020;12:9429-9434. doi: 10.2147/CMAR.S267523. Retrospective analysis. _




Makarevic A, Rapp C, Dettling S, Reuss D, Jungk C, Abdollahi A, von Deimling A, Unterberg A, Herold-Mende C, Warta R.
Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma.
Int J Mol Sci. 2020 Oct 21. 2020;21(20):7801. doi: 10.3390/ijms21207801. Laboratory investigation. _




Regnery S, Behl NGR, Platt T, Weinfurtner N, Windisch P, Deike-Hofmann K, Sahm F, Bendszus M, Debus J, Ladd ME, Schlemmer HP, Rieken S, Adeberg S, Paech D.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Neuroimage Clin. 2020 Sep 12. 2020;28:102427. doi: 10.1016/j.nicl.2020.102427. Prospective study. _




Sakai Y, Yang C, Kihira S, Tsankova N, Khan F, Hormigo A, Lai A, Cloughesy T, Nael K.
MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
Int J Mol Sci. 2020 Oct 27. 2020;21(21):E8004. doi: 10.3390/ijms21218004. PMID: 33121211. Radiomic analysis. _



High-grade gliomas



Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA.
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
JAMA Oncol. 2020 Oct 29:e203161. doi: 10.1001/jamaoncol.2020.3161. Randomized trial. _



*

Hu C, Lin Q, Liu C, Liu J, Chen X, Li X, Zhao G, Zhang L.
Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China.
Cancer Chemother Pharmacol. 2020 Oct 21. 2020;86(6):793-801. doi: 10.1007/s00280-020-04175-0. Randomized trial. _



Low-grade gliomas



Li G, Wu F, Zeng F, Zhai Y, Feng Y, Chang Y, Wang D, Jiang T, Zhang W.
A novel DNA repair-related nomogram predicts survival in low-grade gliomas.
CNS Neurosci Ther. 2020 Oct 16. doi: 10.1111/cns.13464. Nomogram development. _




Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J, Pajtler KW, Sahm F, Bahr A, Simon M, Jones DTW, Well L, Mautner VF, Capper D, Hernáiz Driever P, Gnekow A, Pfister SM, Witt O, Milde T.
Response to trametinib treatment in progressive pediatric low-grade glioma patients.
J Neurooncol. 2020 Oct 7. 2020;149(3):499-510. doi: 10.1007/s11060-020-03640-3. Retrospective analysis. _




Wang Y, Wang Z, Zhao B, Chen W, Wang Y, Ma W.
Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Cancer Med. 2020 Oct 13. doi: 10.1002/cam4.3530. Nomogram development. _



Diffuse astrocytic and oligodendroglial tumors


Butenschoen VM, Hubertus V, Janssen IK, Onken J, Wipplinger C, Mende KC, Eicker SO, Kehl V, Thomé C, Vajkoczy P, Schaller K, Gempt J, Meyer B, Wostrack M.
Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series.
J Neurooncol. 2020 Oct 22. doi: 10.1007/s11060-020-03647-w. Retrospective analysis. _



Glioblastoma



Awada G, Ben Salama L, De Cremer J, Schwarze JK, Fischbuch L, Seynaeve L, Du Four S, Vanbinst AM, Michotte A, Everaert H, Rogiers A, Theuns P, Duerinck J, Neyns B.
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
J Immunother Cancer. 2020 Oct 16. 2020;8(2):e001146. doi: 10.1136/jitc-2020-001146. Phase 2 trial. _




Awada G, Serruys D, Schwarze JK, Van De Voorde L, Duerinck J, Neyns B.
Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1.
Case Rep Oncol. 2020 Sep 1. 2020;13(2):1031-1036. doi: 10.1159/000509773. Case report. _




Certo F, Altieri R, Maione M, Schonauer C, Sortino G, Fiumanò G, Tirrò E, Massimino M, Broggi G, Vigneri P, Magro G, Visocchi M, Barbagallo GMV.
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series.
Oper Neurosurg (Hagerstown). 2020 Oct 9. 2020;opaa293. doi: 10.1093/ons/opaa293. Prospective case series. _




Chen C, Zheng A, Ou X, Wang J, Ma X.
Comparison of Radiomics-Based Machine-Learning Classifiers in Diagnosis of Glioblastoma From Primary Central Nervous System Lymphoma.
Front Oncol. 2020 Sep 15. 2020;10:1151. doi: 10.3389/fonc.2020.01151. Radiomic analysis. _




Chen X, Zeng M, Tong Y, Zhang T, Fu Y, Li H, Zhang Z, Cheng Z, Xu X, Yang R, Liu Z, Wei X, Jiang X.
Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis.
Biomed Res Int. 2020 Sep 23. 2020;2020:9258649. doi: 10.1155/2020/9258649. Artificial intelligence analysis. _




Dastghaib S, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson JB, Samali A, Mokarram P, Ghavami S.
Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Cells. 2020 Oct 22. 2020;9(11):E2339. doi: 10.3390/cells9112339. Laboratory investigation. _




Franco P, Delev D, Cipriani D, Neidert N, Kellner E, Masalha W, Mercas B, Mader I, Reinacher P, Weyerbrock A, Fung C, Beck J, Heiland DH, Schnell O.
Surgery for IDH1/2 wild-type glioma invading the corpus callosum.
Acta Neurochir (Wien). 2020 Oct 23. doi: 10.1007/s00701-020-04623-z. Retrospective analysis. _




Ho KG, Uhlmann EN, Wong ET, Uhlmann EJ.
Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma.
Mol Clin Oncol. 2020 Oct 1. 2020;13(6):80. doi: 10.3892/mco.2020.2150. Retrospective analysis. _




Hsu PYH, Folkman F, Ghosh S, de Robles P, Leckie C, Dersch-Mills D, Coppens R, Chambers C.
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
J Oncol Pharm Pract. 2020 Oct 29. doi: 10.1177/1078155220968613. Retrospective analysis. _




Huang R, Li G, Li Y, Wang Y, Yang P, Zhang C, Wang Z, Zhou D, Zhang W, Zhang Z, Jiang T.
Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults.
Neurooncol Adv. 2020 Aug 21. 2020;2(1):vdaa098. doi: 10.1093/noajnl/vdaa098. Retrospective analysis. _




Peereboom DM, Ye X, Mikkelsen T, Lesser GJ, Lieberman FS, Robins HI, Ahluwalia MS, Sloan AE, Grossman SA.
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
Neurosurgery. 2020 Oct 7:nyaa412. doi: 10.1093/neuros/nyaa412. Phase 2 trial: _ _




Rubin MC, Sagberg LM, Jakola AS, Solheim O.
Primary versus recurrent surgery for glioblastoma-a prospective cohort study.
Acta Neurochir (Wien). 2020 Oct 14. doi: 10.1007/s00701-020-04605-1. Prospective study. _




Saeed AM, Khairnar R, Sharma AM, Larson GL, Tsai HK, Wang CJ, Halasz LM, Chinnaiyan P, Vargas CE, Mishra MV.
Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry.
Adv Radiat Oncol. 2020 Apr 22. 2020;5(5):978-983. doi: 10.1016/j.adro.2020.03.022. Prospective study. _




Stewart J, Sahgal A, Lee Y, Soliman H, Tseng CL, Detsky J, Husain Z, Ho L, Das S, Maralani PJ, Lipsman N, Stanisz G, Perry J, Chen H, Atenafu EG, Campbell M, Lau AZ, Ruschin M, Myrehaug S.
Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study.
Int J Radiat Oncol Biol Phys. 2020 Oct 14. Doi: 10.1016/j.ijrobp.2020.10.002. Prospective study. _




Tzaridis T, Schäfer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberger G, Herrlinger U, Felsberg J.
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33363. Randomized Phase 3 trial.
_



*

Wang LM, Song C, Li YX, Zhang XD, Ji YH, Wen WJ.
A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma.
Chin Med J (Engl). 2020 Oct 15. doi: 10.1097/CM9.0000000000001172. Letter. _



Diffuse midline glioma



DeWire M, Fuller C, Hummel TR, Chow LML, Salloum R, de Blank P, Pater L, Lawson S, Zhu X, Dexheimer P, Carle AC, Kumar SS, Drissi R, Stevenson CB, Lane A, Breneman J, Witte D, Jones BV, Leach JL, Fouladi M.
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
J Neurooncol. 2020 Oct 9. 2020;149(3):511-522. Doi: 10.1007/s11060-020-03641-2. Phase 1-2 trial. _




Dorfer C, Czech T, Gojo J, Hosmann A, Peyrl A, Azizi AA, Kasprian G, Dieckmann K, Filbin MG, Haberler C, Roessler K, Slavc I.
Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas.
Acta Neurochir (Wien). 2020 Oct 22. doi: 10.1007/s00701-020-04589-y. Retrospective analysis. _




Hipp SJ, Goldman S, Kaushal A, Krauze A, Citrin D, Glod J, Walker K, Shih JH, Sethumadhavan H, O'Neill K, Garvin JH, Glade-Bender J, Karajannis MA, Atlas MP, Odabas A, Rodgers LT, Peer CJ, Savage J, Camphausen KA, Packer RJ, Figg WD, Warren KE.
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
J Neurooncol. 2020 Oct 11. 2020;149(3):437-445. doi: 10.1007/s11060-020-03627-0. Phase 1 trial. _



Anaplastic oligodendroglioma



Geben LC, Mobley BC, Brockman AA, Pastakia D, Naftel R, Ihrie RA, Esbenshade AJ.
Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.
Pediatr Blood Cancer. 2020 Oct 1. 2020;e28750. doi: 10.1002/pbc.28750. Case report. _



Other gliomas



Chordoid glioma of the third ventricle



Zhang GB, Huang HW, Li HY, Zhang XK, Wang YG, Lin S.
Intracranial chordoid glioma: A clinical, radiological and pathological study of 14 cases.
J Clin Neurosci. 2020 Sep 18. 2020;80:267-273. doi: 10.1016/j.jocn.2020.09.019. Case series. _



Embryonal tumors



Medulloblastoma



Climans SA, Macdonald DR, Sutherland DE, Mason WP.
Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
BMJ Case Rep. 2020 Oct 29;13(10):e236406. doi: 10.1136/bcr-2020-236406. Case report. _




Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratù G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón Y Cajal S, Poca MA, Puente XS, Sahuquillo J, Gallego S, Seoane J.
Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.
Nat Commun. 2020 Oct 27. 2020;11(1):5376. doi: 10.1038/s41467-020-19175-0. Laboratory investigation. _




Qin Q, Huang D, Jiang Y.
Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study.
Medicine (Baltimore). 2020 Oct 9. 2020;99(41):e22366. Doi: 10.1097/MD.0000000000022366. Retrospective analysis. _




Yan J, Liu L, Wang W, Zhao Y, Li KK, Li K, Wang L, Yuan B, Geng H, Zhang S, Liu Z, Duan W, Zhan Y, Pei D, Zhao H, Sun T, Sun C, Wang W, Hong X, Wang X, Guo Y, Li W, Cheng J, Liu X, Ng HK, Li Z, Zhang Z.
Radiomic Features From Multi-Parameter MRI Combined With Clinical Parameters Predict Molecular Subgroups in Patients With Medulloblastoma.
Front Oncol. 2020 Oct 2;10:558162. doi: 10.3389/fonc.2020.558162. Radiomic analysis. _




Zhu S, Lin F, Chen Z, Jiang X, Zhang J, Yang Q, Chen Y, Wang J.
Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma.
Front Genet. 2020 Sep 3. 2020;11:563882. doi: 10.3389/fgene.2020.563882. Nomogram development. _



Tumors of the sellar region



Craniopharingioma



Prince EW, Whelan R, Mirsky DM, Stence N, Staulcup S, Klimo P, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Limbrick DD Jr, Smith A, Drapeau A, Chern JJ, Kilburn L, Ginn K, Naftel R, Dudley R, Tyler-Kabara E, Jallo G, Handler MH, Jones K, Donson AM, Foreman NK, Hankinson TC.
Robust deep learning classification of adamantinomatous craniopharyngioma from limited preoperative radiographic images.
Sci Rep. 2020 Oct 9. 2020;10(1):16885. doi: 10.1038/s41598-020-73278-8. Radiomic analysis. _



bottom

***********************